Back to Clinical Trials
Phase 2Recruiting

A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma

Sponsored by Amydis Inc.

About this study

The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Open Angle Glaucoma (POAG).

This open-label, masked endpoint assessment study will evaluate safety, tolerability, plasma pharmacokinetics (PK) and biological activity of intravenous (IV) doses of AMDX-2011P in participants with POAG. Assessments of retinal images will be conducted by centrally masked assessors. Participants will be admitted to the study site where eye examination and retinal imaging will be conducted before administration of the study drug. AMDX-2011P will be administered through a single IV bolus injection followed by safety assessments, retinal imaging, and blood collection and PK.

Where this study is enrolling (3)

Who can participate

Inclusion criteria

  • ✓1. Diagnosis of primary open angle glaucoma in both eyes
  • ✓2. Able to fixate
  • ✓3. Glaucomatous optic nerve damage in both eyes, as determined by an investigator as part of an eye exam

Exclusion criteria

  • ✕1. Participants unable to read or write
  • ✕2. Ocular media is not sufficiently clear to obtain acceptable quality images
  • ✕3. Participants with presence of any ocular pathology other than glaucoma in the study eye (cataracts are acceptable)

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.